News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
841,909 Results
Type
Article (86168)
Company Profile (651)
Press Release (755090)
Section
Business (232528)
Career Advice (4125)
Deals (39710)
Drug Delivery (128)
Drug Development (90884)
Employer Resources (198)
FDA (18039)
Job Trends (17313)
News (396103)
Policy (39683)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (7)
2025 Lone Star Bio Digital (9)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2990)
Academic (1)
Accelerated approval (3)
Adcomms (26)
Allergies (86)
Alliances (56741)
ALS (90)
Alzheimer's disease (1458)
Antibody-drug conjugate (ADC) (133)
Approvals (18017)
Artificial intelligence (264)
Autoimmune disease (18)
Automation (14)
Bankruptcy (402)
Best Places to Work (12616)
BIOSECURE Act (21)
Biosimilars (114)
Biotechnology (448)
Bladder cancer (60)
Brain cancer (27)
Breast cancer (257)
Cancer (2069)
Cardiovascular disease (171)
Career advice (3528)
Career pathing (33)
CAR-T (157)
Cell therapy (439)
Cervical cancer (18)
Clinical research (72972)
Collaboration (817)
Compensation (454)
Complete response letters (27)
COVID-19 (2850)
CRISPR (42)
C-suite (219)
Cystic fibrosis (104)
Data (1938)
Decentralized trials (2)
Denatured (43)
Depression (44)
Diabetes (250)
Diagnostics (6860)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (119)
Drug pricing (115)
Drug shortages (29)
Duchenne muscular dystrophy (90)
Earnings (96038)
Editorial (37)
Employer branding (25)
Employer resources (167)
Events (128971)
Executive appointments (651)
FDA (19164)
Featured Employer (65)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (723)
Gene editing (108)
Generative AI (25)
Gene therapy (314)
GLP-1 (796)
Government (5104)
Grass and pollen (4)
Guidances (48)
Healthcare (20850)
Huntington's disease (24)
IgA nephropathy (24)
Immunology and inflammation (121)
Indications (27)
Infectious disease (2984)
Inflammatory bowel disease (146)
Inflation Reduction Act (11)
Influenza (49)
Intellectual property (86)
Interviews (812)
IPO (17787)
IRA (48)
Job creations (5184)
Job search strategy (2861)
Kidney cancer (10)
Labor market (38)
Layoffs (529)
Leadership (20)
Legal (10090)
Liver cancer (76)
Lung cancer (303)
Lymphoma (133)
Machine learning (2)
Management (65)
Manufacturing (296)
MASH (65)
Medical device (14539)
Medtech (14544)
Mergers & acquisitions (22360)
Metabolic disorders (690)
Multiple sclerosis (72)
NASH (23)
Neurodegenerative disease (95)
Neuropsychiatric disorders (30)
Neuroscience (1967)
NextGen: Class of 2025 (7666)
Non-profit (5075)
Northern California (2431)
Now hiring (38)
Obesity (376)
Opinion (269)
Ovarian cancer (74)
Pain (83)
Pancreatic cancer (79)
Parkinson's disease (138)
Partnered (20)
Patents (212)
Patient recruitment (97)
Peanut (51)
People (64976)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase I (22520)
Phase II (31691)
Phase III (23874)
Pipeline (996)
Podcasts (121)
Policy (129)
Postmarket research (3551)
Preclinical (10115)
Press Release (72)
Prostate cancer (93)
Psychedelics (37)
Radiopharmaceuticals (264)
Rare diseases (388)
Real estate (7384)
Recruiting (75)
Regulatory (26564)
Reports (57)
Research institute (2649)
Resumes & cover letters (649)
Rett syndrome (3)
RNA editing (2)
RSV (39)
Schizophrenia (71)
Series A (131)
Series B (83)
Service/supplier (27)
Sickle cell disease (55)
Southern California (2106)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (33)
Startups (4286)
State (2)
Stomach cancer (13)
Supply chain (61)
The Weekly (75)
United States (22020)
Vaccines (757)
Venture capitalists (39)
Webinars (13)
Weight loss (275)
Women's health (38)
Worklife (18)
Date
Today (22)
Last 7 days (589)
Last 30 days (2640)
Last 365 days (35531)
2025 (8031)
2024 (37556)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1269)
Alabama (56)
Alaska (7)
Arizona (257)
Arkansas (14)
Asia (49932)
Australia (8801)
California (5662)
Canada (1881)
China (497)
Colorado (256)
Connecticut (268)
Delaware (131)
Europe (114333)
Florida (827)
Georgia (198)
Hawaii (1)
Idaho (64)
Illinois (558)
India (27)
Indiana (303)
Iowa (10)
Japan (141)
Kansas (107)
Kentucky (25)
Louisiana (10)
Maine (65)
Maryland (888)
Massachusetts (4367)
Michigan (221)
Minnesota (389)
Mississippi (2)
Missouri (78)
Montana (30)
Nebraska (26)
Nevada (58)
New Hampshire (66)
New Jersey (1615)
New Mexico (30)
New York (1614)
North Carolina (1053)
North Dakota (8)
Northern California (2431)
Ohio (197)
Oklahoma (15)
Oregon (45)
Pennsylvania (1269)
Puerto Rico (10)
Rhode Island (28)
South America (1650)
South Carolina (18)
South Dakota (1)
Southern California (2106)
Tennessee (93)
Texas (847)
Utah (168)
Virginia (140)
Washington D.C. (62)
Washington State (545)
West Virginia (3)
Wisconsin (51)
841,909 Results for "adicet bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
February 27, 2025
·
4 min read
Press Releases
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
March 6, 2025
·
11 min read
Press Releases
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
·
1 min read
Press Releases
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
January 8, 2025
·
7 min read
Press Releases
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 31, 2025
February 2, 2025
·
2 min read
Biotech Bay
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.
May 29, 2024
·
1 min read
Biotech Bay
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 28, 2024
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted inducement awards on June 28, 2024.
June 28, 2024
·
2 min read
Press Releases
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
February 5, 2025
·
4 min read
FDA
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
June 5, 2024
·
4 min read
Press Releases
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
December 18, 2024
·
6 min read
1 of 84,191
Next
